Drug Trial Radar · NCT07937852
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Jan 18, 2027
Primary completion
Nov 30, 2029
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
Conditions
- Multiple Sclerosis
Interventions
FenebrutinibDrug
Fenebrutinib will be administered as per the schedule specified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.